In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

The other is a top REIT that cranks out a dividend far more often than the usual U.S. business. It isn't all that difficult ...

After peaking in February 2021, biotech stocks as a group didn't participate once the market turned around after 2022. This ...

One of Cincinnati’s largest private companies saw its stock jump up nearly $50 per share after it reported strong third-quarter earnings.

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Intensity Therapeutics Inc., a clinical-stage biotechnology company based in Shelton, announced this week that its ...

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector ...

This week’s XBI pullback is healthy. Biotech stocks cannot go up every day. The sector’s recovery off the April lows has been ...

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, ...

Bio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry ...

The hedge fund called out a small investment in biotech Coya Therapeutics (COYA), which has just begun clinical trials for a treatment of Lou Gehrig's disease. Greenlight, which is Coya's largest ...

Cardiff Oncology's onvansertib's unique PLK1 inhibition mechanism offers breakthrough potential in multi-billion-dollar ...